NCT00380835撤回2 期
A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 66
- 试验地点
- 28
- 主要终点
- Incidence of cardiac toxicity
研究概览
简要总结
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological diagnosis of breast cancer.
- •Metastatic or recurrent disease, either HER2+ (FISH+ or 3+ IHC) or HER2-.
- •Maximal dose of prior adjuvant anthracycline: 300 mg/meters squared doxorubicin or equivalent. Relapse greater than one year after trastuzumab adjuvantly; two years following adjuvant anthracycline therapy (without trastuzumab).
- •One prior chemotherapy for metastatic breast cancer allowed (may include trastuzumab for HER2+ patients), but no prior Doxil, adriamycin or epirubicin for metastatic breast cancer.
- •At least 18 years of age.
- •ECOG Performance Status of 0, 1, or
- •Adequate organ function including the following:
- •Adequate bone marrow reserve.
- •Cardiac: Left ventricular ejection fraction (LVEF) greater than or equal to 55% by MUGA.
- •Negative serum pregnancy test at the time of enrollment for women of child-bearing potential.
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.
排除标准
- •Pregnant or nursing women.
- •Concurrent anticancer therapy.
- •Participation in any investigational drug study within 28 days prior to study entry.
- •Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, uncontrolled hypertension, coronary artery disease, congestive heart failure, severe arrhythmia) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •Symptomatic central nervous system metastases. Patients with asymptomatic brain metastases are allowed. The patient must be stable after radiotherapy for greater than or equal to 2 weeks and off corticosteroids for greater than or equal to 1 week.
- •History of interstitial lung disease or pulmonary fibrosis.
结局指标
主要结局
Incidence of cardiac toxicity
次要结局
- Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)
- Duration of overall response
- Time to tumor progression
- Progression free survival
- Toxicity profile
研究者
研究点 (28)
Loading locations...
相似试验
已完成
1 期
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT00915083Celgene24
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35
已完成
2 期
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapySmall Cell Lung CancerNCT00375193Celgene75
已完成
2 期
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.Small Cell Lung CancerNCT00319969Celgene Corporation76
已完成
2 期
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung CancerSmall Cell Lung CancerNCT00388960Celgene99